Loading...
Market
What regulatory change will result from Neuralink's N1 chip trial in Canada by end of 2025?
2
Resolution / Starting Odds
New safety guidelines • 25%
Faster approval processes for BCI • 25%
Stricter regulations • 25%
No regulatory changes • 25%
Health Canada announcements or Canadian government publications
Story
Neuralink Approved for First Clinical Trial in Canada Using N1 Chip for ALS and SCI Patients
Nov 20, 2024, 07:51 PM
Neuralink has received approval from Health Canada to initiate recruitment for its first clinical trial in Canada, aimed at individuals with quadriplegia due to ALS or spinal cord injury (SCI). The trial will utilize Neuralink's N1 chip, which enables paralyzed individuals to control devices such as computers through brain-computer interface (BCI) technology. This advancement is expected to have a transformative impact on the lives of many. Interested participants can find more information and apply through Neuralink's Patient Registry.
View original story
Similar markets
No action taken • 25%
Trial paused • 25%
Additional conditions imposed • 25%
Trial revoked • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Yes • 50%
No • 50%
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Regulatory issues • 25%
Technical failures • 25%
Patient recruitment difficulties • 25%
No major challenges • 25%